Skip to main content
TipRanks
Go Ultimate75% OFF

Context Therapeutics (CNTX) Stock Statistics & Valuation Metrics

330 Followers

Total Valuation

Context Therapeutics has a market cap or net worth of $16.61M. The enterprise value is -$5.61M.

Market Cap
$16.61M
Enterprise Value
-$5.61M

Share Statistics

Context Therapeutics has 91,879,170 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
91,879,170
Owned by Insiders
1.35%
Owned by Institutions
23.86%

Financial Efficiency

Context Therapeutics’s return on equity (ROE) is -0.60 and return on invested capital (ROIC) is -65.53%.

Return on Equity (ROE)
-0.60
Return on Assets (ROA)
-0.53
Return on Invested Capital (ROIC)
-65.53%
Return on Capital Employed (ROCE)
-0.66
Revenue Per Employee
0
Profits Per Employee
-2.41M
Employee Count
15
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Context Therapeutics is -0.39. Context Therapeutics’s PEG ratio is 0.01.

PE Ratio
-0.39
PS Ratio
0.00
PB Ratio
0.56
Price to FCF
-0.49
Price to Operating Cash Flow
-0.51
PEG Ratio
0.01

Income Statement

In the last 12 months, Context Therapeutics had revenue of 0 and earned -36.12M in profits. Earnings per share was -0.38.

Revenue
0
Gross Profit
0
Operating Income
-39.70M
Pretax Income
-36.12M
Net Income
-36.12M
EBITDA
-36.11M
Earnings Per Share (EPS)
-0.38

Cash Flow

In the last 12 months, operating cash flow was -33.97M and capital expenditures -55,749, giving a free cash flow of -34.03M billion.

Operating Cash Flow
-33.97M
Free Cash Flow
-34.03M
Free Cash Flow per Share
-0.36

Dividends & Yields

Context Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-204.84%
Earnings Yield
-255.03%

Stock Price Statistics

Beta
0.90
52-Week Price Change
-84.35%
50-Day Moving Average
0.28
200-Day Moving Average
1.35
Relative Strength Index (RSI)
33.44
Average Volume (3m)
1.48M

Important Dates

Context Therapeutics upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 10, 2026
Next Earnings Date
Mar 24, 2027
Ex-Dividend Date
―

Financial Position

Context Therapeutics as a current ratio of 8.52, with Debt / Equity ratio of 0.19%

Current Ratio
8.52
Quick Ratio
8.52
Debt to Market Cap
0.00
Net Debt to EBITDA
1.82
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Context Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Context Therapeutics EV to EBITDA ratio is 0.40, with an EV/FCF ratio of 0.52.

EV to Sales
0.00
EV to EBITDA
0.40
EV to Free Cash Flow
0.52
EV to Operating Cash Flow
0.52

Balance Sheet

Context Therapeutics has $34.41M in cash and marketable securities with $206.52K in debt, giving a net cash position of $34.20M billion.

Cash & Marketable Securities
$34.41M
Total Debt
$206.52K
Net Cash
$34.20M
Net Cash Per Share
$0.37
Tangible Book Value Per Share
$0.33

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Context Therapeutics is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$5.00
Price Target Upside
2677.78% Upside
Analyst Consensus
Moderate Buy
Analyst Count
2
Revenue Growth Forecast
―
EPS Growth Forecast
-66.49%

Scores

Smart Score
―
AI Score
45